Clinical Research Directory
Browse clinical research sites, groups, and studies.
Investigation to Understand and Optimize Psilocybin
Sponsor: Charles Raison
Summary
This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.
Official title: An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
141
Start Date
2025-05-13
Completion Date
2029-05
Last Updated
2025-05-23
Healthy Volunteers
No
Conditions
Interventions
Psilocybin
The psilocybin used in this study is synthesized under Good Manufacturing Practice (GMP) guidelines and is provided in a capsule containing 25 mg of synthetic psilocybin.
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear.
Sham taVNS
Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear. In the sham condition, the device will simulate the sensations of active taVNS without delivering therapeutic stimulation.
Locations (1)
Vail Health Behavioral Health
Edwards, Colorado, United States